GENFIT (GNFT) Competitors $3.97 +0.19 (+4.92%) Closing price 07/23/2025 03:53 PM EasternExtended Trading$3.97 +0.01 (+0.20%) As of 07/23/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. AVBP, VIR, IOVA, AMLX, SION, CRMD, TNGX, IMTX, STOK, and URGNShould you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include ArriVent BioPharma (AVBP), Vir Biotechnology (VIR), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), Sionna Therapeutics (SION), CorMedix (CRMD), Tango Therapeutics (TNGX), Immatics (IMTX), Stoke Therapeutics (STOK), and Urogen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry. GENFIT vs. Its Competitors ArriVent BioPharma Vir Biotechnology Iovance Biotherapeutics Amylyx Pharmaceuticals Sionna Therapeutics CorMedix Tango Therapeutics Immatics Stoke Therapeutics Urogen Pharma GENFIT (NASDAQ:GNFT) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings. Does the media prefer GNFT or AVBP? In the previous week, ArriVent BioPharma had 9 more articles in the media than GENFIT. MarketBeat recorded 9 mentions for ArriVent BioPharma and 0 mentions for GENFIT. ArriVent BioPharma's average media sentiment score of 0.65 beat GENFIT's score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Overall Sentiment GENFIT Neutral ArriVent BioPharma Positive Which has better valuation & earnings, GNFT or AVBP? GENFIT has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENFIT$76.77M2.58$1.63MN/AN/AArriVent BioPharmaN/AN/A-$80.49M-$3.77-5.81 Is GNFT or AVBP more profitable? GENFIT's return on equity of 0.00% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets GENFITN/A N/A N/A ArriVent BioPharma N/A -49.21%-46.61% Do analysts rate GNFT or AVBP? GENFIT presently has a consensus price target of $13.00, suggesting a potential upside of 227.79%. ArriVent BioPharma has a consensus price target of $39.29, suggesting a potential upside of 79.47%. Given GENFIT's higher probable upside, equities research analysts clearly believe GENFIT is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has more volatility and risk, GNFT or AVBP? GENFIT has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Do institutionals & insiders hold more shares of GNFT or AVBP? 2.2% of GENFIT shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.2% of GENFIT shares are held by company insiders. Comparatively, 18.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryArriVent BioPharma beats GENFIT on 8 of the 13 factors compared between the two stocks. Get GENFIT News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGENFITMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$189.01M$2.99B$5.57B$9.42BDividend YieldN/A2.44%4.05%3.99%P/E RatioN/A21.2528.1520.08Price / Sales2.58253.33401.6884.07Price / Cash54.0441.9636.1958.45Price / Book2.648.198.625.83Net Income$1.63M-$55.10M$3.24B$258.27M7 Day Performance3.15%5.56%3.55%2.69%1 Month Performance3.01%18.19%11.01%12.91%1 Year Performance-6.24%7.32%35.56%21.81% GENFIT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGENFIT2.2908 of 5 stars$3.97+4.9%$13.00+227.8%-5.7%$189.01M$76.77M0.00120Gap UpAVBPArriVent BioPharma2.27 of 5 stars$21.55-2.3%$39.29+82.3%+7.1%$754.39MN/A-5.7240Analyst ForecastAnalyst RevisionVIRVir Biotechnology3.691 of 5 stars$5.52+2.0%$30.25+448.0%-42.6%$747.87M$74.21M-1.31580IOVAIovance Biotherapeutics4.6346 of 5 stars$2.49+11.7%$12.22+390.9%-54.3%$744.67M$212.68M-2.01500Analyst ForecastOptions VolumeGap UpHigh Trading VolumeAMLXAmylyx Pharmaceuticals3.3162 of 5 stars$8.21-1.6%$11.75+43.1%+328.1%$743.44M$87.37M-2.64200SIONSionna TherapeuticsN/A$17.44+4.2%$38.50+120.8%N/A$738.64MN/A0.0035CRMDCorMedix2.8938 of 5 stars$10.94+0.7%$17.14+56.7%+140.6%$736.58M$43.47M49.7330TNGXTango Therapeutics1.3529 of 5 stars$6.77flat$10.50+55.1%-29.4%$733.83M$42.07M-5.5590Gap UpIMTXImmatics3.0863 of 5 stars$5.85-2.5%$14.67+150.7%-50.1%$729.30M$168.65M-34.41260News CoveragePositive NewsSTOKStoke Therapeutics4.2718 of 5 stars$12.31-6.9%$25.80+109.6%-2.1%$721.77M$36.56M15.58100Gap UpURGNUrogen Pharma4.5083 of 5 stars$15.46+1.2%$32.86+112.5%+10.2%$705.49M$91.87M-4.86200High Trading Volume Related Companies and Tools Related Companies ArriVent BioPharma Alternatives Vir Biotechnology Alternatives Iovance Biotherapeutics Alternatives Amylyx Pharmaceuticals Alternatives Sionna Therapeutics Alternatives CorMedix Alternatives Tango Therapeutics Alternatives Immatics Alternatives Stoke Therapeutics Alternatives Urogen Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
